CorMedix To Pay $145 Million Plus Stock For Heron's Pain And Nausea Drugs
Management expects $45 million–$60 million in annual savings by year-end 2027 as it adds four drugs to its hospital sales platform.
CorMedix, which develops and sells treatments for life-threatening conditions, agreed Sunday to buy substantially all of Heron Therapeutics' assets for $145 million in cash, subject to adjustments, plus 14,583,333 shares. The deal, announced Monday and detailed in an SEC filing, would add postsurgical pain and nausea medicines to its hospital-focused portfolio; management expects earnings and free cash flow to increase immediately upon closing.
Four Drugs, An Existing Sales Force
Heron's portfolio generated approximately $150 million in net product revenue over the twelve months ended September 30, 2026. CorMedix estimates combined-business revenue of $465 million–$490 million for 2026 and $125 million–$150 million from the acquired assets in 2027. Those estimates combine the companies' projected results without further adjustments.
The purchase adds ZYNRELEF for postsurgical pain and APONVIE to prevent postsurgical nausea and vomiting. CINVANTI and SUSTOL prevent nausea and vomiting associated with chemotherapy. CorMedix would also take over Heron's rights under a multi-product development and licensing agreement.
CorMedix's largest net-sales contributor is DefenCath, a solution used in catheters to reduce bloodstream infections in adults with kidney failure receiving chronic hemodialysis. Its August 29, 2025 purchase of Melinta Therapeutics added infectious-disease medicines and helped build a sales organization serving hospitals, infusion centers and dialysis clinics.
Management expects to use that infrastructure for Heron's drugs and eliminate overlapping commercial, administrative and public-company costs. It projects annual operating savings of $45 million–$60 million by year-end 2027.
Joseph Todisco, CorMedix's chairman and chief executive officer, called ZYNRELEF an asset with “significant untapped potential” as hospitals and surgery centers increasingly adopt “non-opioid approaches to postsurgical pain”.
Fixed Shares, Sales-Linked Payments
The upfront package was worth approximately $222.6 million using CRMD's $5.32 share price at Friday's close, including approximately $77.6 million in stock. The share count is fixed: subsequent price changes would alter its value, rather than the number of shares issued.
Heron could receive another $25 million if ZYNRELEF's 2028 net sales reach $65 million, and an additional $30 million if they reach $95 million. CorMedix can pay those amounts in cash, stock or both, with cash required for any portion that would push aggregate shares issued under the deal above the agreement's 19.9% limit.
Heron would also receive a 5% royalty on the portion of combined annual net sales above $25 million from CINVANTI, SUSTOL and the licensed products in each of 2027, 2028 and 2029.
New Debt, A Different Heron
CorMedix plans to borrow $75 million at closing through a new $150 million secured loan facility from Pharmakon-managed funds. The other $75 million tranche would support additional business-development transactions. Interest is set at the three-month Term SOFR benchmark, with a 3.50% floor, plus 5.75% annually.
Heron intends to exit its operating business without liquidating and remain publicly traded, holding CorMedix shares, cash and contingent-payment rights while repaying its Hercules credit facility. It also retains approximately $2.3 billion in federal and state tax-loss carryforwards as of September 30, 2026, and plans to evaluate investments or acquisitions that need not be biotechnology businesses.
Rubric Capital Management agreed to exchange Heron's convertible-note debt for some of the CorMedix shares Heron receives. The debt totaled approximately $37.8 million including interest as of September 30, 2026; the exchange is expected in four quarterly installments after closing. Heron would have the right to designate a CorMedix director while holding at least 10% of its outstanding shares.
Both boards approved the deal unanimously. Heron holders representing approximately 22% of its outstanding shares have agreed to support it; CorMedix shareholders do not need to vote.
CorMedix expects the purchase to close in the first quarter of 2027, pending Heron shareholder approval and regulatory clearance. Its third-quarter results are scheduled for Thursday.
Sources
- 8-K Filing — CorMedix Inc. (CRMD) — SEC EDGAR
- Exhibit ea031142301ex99-1.htm — CorMedix Inc. 8-K exhibit — SEC EDGAR
- CorMedix Therapeutics to Acquire Substantially All Assets — globenewswire.com